Johnson & Johnson (NYSE:JNJ) Shares Bought by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 141.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 7,174 shares of the company’s stock after purchasing an additional 4,198 shares during the period. Legacy Capital Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,049,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. GUNN & Co INVESTMENT MANAGEMENT INC. boosted its stake in shares of Johnson & Johnson by 1,194.9% during the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after acquiring an additional 218,949 shares during the last quarter. Gilbert & Cook Inc. boosted its stake in shares of Johnson & Johnson by 3.3% during the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after acquiring an additional 288 shares during the last quarter. Concentrum Wealth Management boosted its stake in shares of Johnson & Johnson by 5.1% during the fourth quarter. Concentrum Wealth Management now owns 2,193 shares of the company’s stock valued at $344,000 after acquiring an additional 106 shares during the last quarter. Westover Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 5.8% during the fourth quarter. Westover Capital Advisors LLC now owns 3,328 shares of the company’s stock valued at $522,000 after acquiring an additional 182 shares during the last quarter. Finally, Smart Money Group LLC boosted its stake in shares of Johnson & Johnson by 9.0% during the fourth quarter. Smart Money Group LLC now owns 3,865 shares of the company’s stock valued at $606,000 after acquiring an additional 318 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on JNJ. The Goldman Sachs Group decreased their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. TD Securities reduced their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $167.27 on Thursday. The stock’s 50-day moving average is $156.82 and its 200-day moving average is $153.70. The company has a market cap of $402.57 billion, a price-to-earnings ratio of 10.43, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business posted $2.80 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.